Vandetanib 443913-73-3 Anti-Cancer 99% Assay Quick Effect Raw Powder

Basic Information
Place of Origin: CHINA
Brand Name: TINGYI
Certification: GMP , ISO 9001:2008
Model Number: 443913-73-3
Minimum Order Quantity: 10g
Price: Contact Me
Packaging Details: Disguised Package
Delivery Time: 2 Working Days
Payment Terms: Bank Transfer - Bitcoin - Western Union - MoneyGram
Supply Ability: 100 KG/Month
Product Name: Vandetanib CAS: 443913-73-3
Appearance: White Powder Usage: Nervous System Drug
Shipping Method: EMS, HKEMS, FEDEX, DHL, UPS, Aramex, ETC Color: White
High Light:

pharmaceutical active ingredients

,

pharmaceutical anabolic steroids

 


Basic Information

Product Name Vandetanib
CAS 443913-73-3
Purity 99%
Molecular Formula C22H24BrFN4O2
Molecular Weight 475.35
Molecular Structure Vandetanib 443913-73-3 Anti-Cancer 99% Assay Quick Effect Raw Powder 0
Payment Method Western Union, Bank Transfer, MoneyGram, Bitcoin, Litecoin

Vandetanib 443913-73-3 Anti-Cancer 99% Assay Quick Effect Raw Powder 1

 

 

Application


Vandetanib is used to treat a certain type of thyroid cancer that cannot be treated by surgery or that has spread to other parts of the body. Vandetanib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor-2 and epidermal growth factor receptor kinase activity. The activity of Vandetanib plus Docetaxel was assessed in patients with previously treated non-small-cell lung cancer (NSCLC).

 

Vandetanib was the first drug to be approved by FDA (April 2011) for treatment of late-stage (metastatic) medullary thyroid cancer in adult patients who are ineligible for surgery. Vandetanib was first initially marketed without a trade name, and is being marketed under the trade name Caprelsa since August 2011. Vandetanib is a type of biological therapy. It is a cancer growth blocker, which stops signals (chemical messengers) that cancer cells use to divide and grow. An anticancer drug that is used for the treatment of certain tumours of the thyroid gland.It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase. Vandetanib is an orally active small molecule tyrosine kinase inhibitor (TKI) with activity against several pathways implicated in malignancy including the vascular endothelial growth factor receptor pathway, the epidermal growth factor receptor pathway, the platelet derived growth factor receptor pathway, and REarranged during Transfection pathway.

 

 

 

Usage And Synthesis


(1).Anti-cancer drugs


Vandetanib is a kind of small molecule multi-targeted tyrosine kinase inhibitor studied and developed by the British AstraZeneca Company. In April 2011, it was approved the US FDA for entering into market under the trade name Zactima. The drug, as a tablet, can be applied to the treatment of advanced medullary thyroid cancer of adult patients.


Vandetanib is a multi-targeted tyrosine kinase inhibitor, and belongs to the Anilinoquinazoline compounds, called "second generation Iressa". It not only acts on the tumor cells, EGFR, VEGFR and RET tyrosine kinases, but can also inhibit other kind of tyrosine kinases and serine / threonine kinases. Vandetanib is the first approved drugs approved for treatment of medullary thyroid carcinoma. It is suitable for treating unresectable, locally advanced or metastatic-symptoms or progressive medullary thyroid carcinoma.

 

A randomized, placebo-controlled clinical trial results have showed that vandetanib can significantly delay the progression time of locally advanced or metastatic medullary thyroid cancer. The recommended daily dose is 300 mg (oral), when the patient exhibits tolerance to drugs or being not able to tolerate the toxicity, they should stop treatment immediately. Those most common adverse reactions of this medicine include diarrhea, rash, acne, nausea, hypertension, headache, fatigue, loss of appetite and abdominal pain. The adverse reactions is dose-related; at <300 mg/d, the patient has a well tolerance with the maximum tolerated dose (MTD) being 300mg. There are many kinds disease types contained in the II phase clinical study. The NSCLC clinical trials of vandetanib are currently under way for our country.


(2).Treatment of advanced (non-small cell lung cancer) NSCLC


A study published in the [Journal of Clinical Oncology] have showed that compared with gefitinib which only has inhibitory effect on EGFR, vandetanib can effectively extend the progression-free survival period of the non-small cell lung cancer (NSCLC) patients.


In this phase II clinical trial conducted by doctors Ronald B. Natale from Los Angeles Cedars-Sinai Cancer Center, clinical study compared the treatment efficacy of vandetanib (300 mg/d) and gefitinib (250mg/d) on 168 cases of NSCLC patients who had been subject to failing first-line or second-line chemotherapy. Compared with gefitinib, vandetanib significantly increased efficiency and prolonged the progression-free survival, period respectively, by 8% and 1%, 11.9 weeks and 8.1 weeks, (P = 0.011). In clinical trials, if there is progression of the disease or if the patient can't tolerate the toxicity, they allowed the patients to change the treatment regimen. Experimental results had shown that using gefitinib for replacing vandetanib in patients gave a disease control rate of 14% while using vandetanib to replace gefitinib gave a disease control rate of 32%. The overall survival period in the case of vandetanib → gefitinib was 6.1 months while it was 7.4 months in the cases of gefitinib → vandetanib.


(3).Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor-2 and epidermal growth factor receptor kinase activity. The activity of Vandetanib plus Docetaxel was assessed in patients with previously treated non-small-cell lung cancer (NSCLC).

 

 

 

FAQ


Q1: Have your Product Quality been Approved by Third Party Lab ?
A: Yes, All products are strictly tested by our QC, confirmed by QA and approved by third party lab in China, USA, Canada, Germany, UK, Italy, France etc. So you will be assured with Good Quality if you choose us.


Q2. Are you a manufacturer?
A: Yes, we have our own factory and lab.

 

Q3: Is there any discount?
A: Yes, as for old customers and larger quantity, we always support with great discounts and surprise.

 

Q4:Do you accept VISA business credit card ?
A:Sorry we don't accept VISA credit card, we'd like to accept Western Union, MoneyGram, Bank Transfer, Bitcoin, Litecoin.

 

Q5: How do you treat quality complaint?
A: First of all, our QC department will do strict examination of our export products in order to reduce the quality problem to near zero. If there is a real quality problem caused by us, we will send you free goods for replacement or refund your loss.


Q6: How to proceed order?

1st: Please let me know what you need-Which product/Cas No. quantity, and the destination country.
2nd: You send us the purchase order once we come to an agreement on all details.
3rd: Parcel would be delivered upon full payment received.
4th: Express Tracking No.will be provided about the parcels.
5th: You will get the parcels within 7days.
6th: After-sales service would be provided after you receive parcels.

Vandetanib 443913-73-3 Anti-Cancer 99% Assay Quick Effect Raw Powder 2

 


Related Nervous System Drug ( Raw Powder)

Oxcarbazepine
Atropine
Pregabalin
Flumazenil
Carbamazepine
Amlodipine
Pramipexole
Clozapine
NSI-189
Xylazine hydrochloride
Propranolol hydrochloride
Lamotrigine
Vandetanib
Trazodone hydrochloride
Levetiracetam
Reserpine
Tianeptine
Nepafenac
Donepezil Hydrochloride
Tianeptine sodium salt
Dioxopromethaxine HCL
 

Contact Details
Sales Manager

WhatsApp : +8613657291547